Globenewswire
Search documents
Annual Results 2025: clear second half improvement, restructuring measures show first results
Globenewswire· 2026-02-26 05:30
Ad hoc announcement pursuant to Article 53 LR26 February 2026 – 06:30 AMThe Feintool Group’s business performance in the 2025 financial year reflects a market environment that remains challenging, with differing dynamics across regions and technologies. The global automotive market is growing at a low single-digit rate, while shifts in climate policy and subsidy schemes – particularly in the United States – are influencing investment decisions and the pace of electrification. At the same time, demand for in ...
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Globenewswire· 2026-02-26 05:30
Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information February 26, 2026, 6:30 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives o ...
Inbank unaudited financial results for Q4 and 12 months of 2025
Globenewswire· 2026-02-26 05:30
In 2025, Inbank’s consolidated net profit increased to €19.2 million, up 57% year-on-year. Return on equity (ROE) improved to 12.3% for the full year. In Q4 2025, Inbank earned a net profit of €6.1 million, increasing 339% year-on-year, and ROE for Q4 reached 14.7%. In 2025, total net income reached €85.1 million, increasing 13% year-on-year, while operating expenses remained broadly flat at €46.3 million. As a result, net profit increased 57% to €19.2 million and return on equity improved to 12.3%. The co ...
CGTN: Merz's China visit injects fresh momentum into China-Germany, China-Europe ties
Globenewswire· 2026-02-26 04:24
CGTN published an article on German Chancellor Friedrich Merz's official visit to China from February 25 to 26. The article highlights the significance of the visit and analyzes – from economic and political perspectives – how China and Germany have written a successful story of win-win cooperation, and how their partnership injects stability into China-Europe relations and global governance. BEIJING, Feb. 25, 2026 (GLOBE NEWSWIRE) -- German automaker BMW announced plans in April 2025 to start integrating a ...
InnoCare Announces Key Developments of Critical Clinical Studies
Globenewswire· 2026-02-26 03:56
Core Viewpoint - InnoCare Pharma has made significant progress in clinical development, completing patient enrollment in multiple Phase III registrational trials for its cancer and autoimmune disease treatments [1] Group 1: Clinical Development Progress - The company completed patient enrollment in a Phase III trial for the BCL2 inhibitor mesutoclax (ICP-248) combined with BTK inhibitor orelabrutinib for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients [2] - InnoCare has also accelerated the clinical development of two novel TYK2 inhibitors, completing patient enrollment in the Phase III trial of soficitinib (ICP-332) for moderate to severe atopic dermatitis and in the Phase III trial of ICP-488 for psoriasis [4] - Additionally, patient enrollment has been completed in a Phase II trial of soficitinib for vitiligo, targeting various T-cell related autoimmune disorders [5] Group 2: Drug Mechanisms and Indications - Mesutoclax is a selective oral BCL2 inhibitor that restores normal apoptosis in cancer cells, aiming to provide deeper remission for treatment-naïve CLL/SLL patients [3] - Soficitinib is a potent TYK2 inhibitor being developed for multiple dermatological conditions, including atopic dermatitis, vitiligo, prurigo nodularis, CSU, and psoriasis [5][6] - ICP-488, an oral allosteric TYK2 inhibitor, blocks inflammatory cytokine signaling pathways, addressing autoimmune and inflammatory diseases [6] Group 3: Company Overview - InnoCare is a commercial stage biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases with unmet medical needs [7]
Navan Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Navan, Inc. - NAVN
Globenewswire· 2026-02-26 03:16
Core Viewpoint - ClaimsFiler informs investors about the deadline of April 24, 2026, to file lead plaintiff applications in a securities class action lawsuit against Navan, Inc. related to its October 2025 IPO [1] Group 1: Lawsuit Details - Navan and certain executives are accused of failing to disclose material information during the Class Period, violating federal securities laws [3] - The lawsuit claims that Navan increased its "sales and marketing" expenses for the quarter ending October 31, 2025, to nearly $95 million, a 39% increase from $68.5 million in the quarter ending July 31, 2025 [3] - Following the revelation of true details, Navan's shares reportedly fell sharply [3] Group 2: Legal Assistance - Investors can visit ClaimsFiler's website or call a toll-free number for assistance regarding their legal options [2] - ClaimsFiler provides a platform for retail investors to recover funds from securities class action settlements [5]
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
Globenewswire· 2026-02-26 03:14
Core Viewpoint - ClaimsFiler is reminding investors of the deadline to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics, related to undisclosed material information during the Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that Corcept and its executives failed to disclose material information, violating federal securities laws during the Class Period from October 31, 2024, to December 30, 2025 [3]. - The complaint specifically mentions that Corcept misled investors regarding the likelihood of FDA approval for its product candidate, relacorilant, following its New Drug Application submission [4]. - Following the disclosure of a Complete Response Letter from the FDA on December 31, 2025, which indicated that additional evidence of effectiveness was needed, Corcept's share price fell by $35.40, or 50.4%, from $70.20 to $34.80 [4]. Group 2: Legal and Investor Support - The case is officially titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 [5]. - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information access and case evaluations [6].
Enphase Energy Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Enphase Energy, Inc. - ENPH
Globenewswire· 2026-02-26 02:58
Core Viewpoint - Enphase Energy, Inc. is facing a securities class action lawsuit for allegedly failing to disclose material information during the class period from April 22, 2025, to October 28, 2025, which may have misled investors [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the United States District Court for the Northern District of California [1]. - The case is identified as Tripathi v. Enphase Energy, Inc., No. 26-cv-01380 [4]. - Allegations include that Enphase overstated its ability to manage channel inventory and offset impacts from the termination of the Residential Clean Energy Credit, leading to an overstatement of its financial and operational prospects [4]. Group 2: Investor Information - Investors have until April 20, 2026, to file lead plaintiff applications if they purchased Enphase securities during the specified class period [1]. - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for access to information and case evaluations [5].
DMG Blockchain Solutions Reports First Quarter 2026 Financial Results
Globenewswire· 2026-02-26 02:25
Core Insights - DMG Blockchain Solutions Inc. reported its fiscal first quarter 2026 unaudited financial results, highlighting a focus on its core data center operations and digital asset financial services [1][3] Financial Performance - Revenue for Q1 2026 was $11.2 million, a decrease of 4% from $11.6 million in Q1 2025, primarily due to a $1.8 million drop in digital currency mining revenues, partially offset by $1.5 million from energy efficiency incentives [4][10] - Operating and maintenance expenses remained stable at $6.7 million, while general and administrative costs slightly increased to $1.9 million due to higher consulting fees related to AI strategy investments [5] - Depreciation expenses decreased to $3.5 million from $4.3 million in Q1 2025, reflecting the declining balance depreciation method [6] - The net loss for Q1 2026 was $2.2 million, an improvement from a net loss of $3.1 million in Q1 2025, attributed to reduced operating losses and foreign exchange impacts [7] - Comprehensive income/loss showed a significant decline, moving from a gain of $12.2 million in Q1 2025 to a loss of $16.5 million in Q1 2026, mainly due to unrealized valuation losses on digital currency [8] Asset and Cash Position - Total assets as of December 31, 2025, were $122.0 million, down from $132.0 million at the end of September 2025, driven by a $6.0 million decrease in digital asset valuations and $3.1 million in fixed asset depreciation [9][10] - Cash, short-term investments, and digital assets totaled $58.6 million at the end of Q1 2026, a decrease of 10% from $65.2 million at year-end 2025 [10] Operational Highlights - The company mined 69 bitcoins in Q1 2026, down from 97 bitcoins in Q1 2025, while the hashrate increased by 10% to 1.76 EH/s [10] - DMG is converting its Christina Lake facility into an AI data center with a capacity of at least 50 megawatts, aiming to fill an industry gap in available capacity [3] Future Outlook - The company is actively pursuing AI off-takers and potential government partnerships to drive future revenue growth through its Systemic Trust initiative [3]
VOOPOO DRAG 6 First Look: Legendary GENE TT 3.0 Chipset and All-New UFORCE-X Tank II Exposed
Globenewswire· 2026-02-26 02:22
Core Insights - The vaping industry continues to evolve with new product formats, yet high-performance mods like VOOPOO's DRAG series remain popular among seasoned vapers [1] - The upcoming DRAG 6 is set to launch in March 2026, featuring significant innovations such as the GENE TT 3.0 chip and the UFORCE-X Tank II [2] Group 1: Product Highlights - VOOPOO's DRAG 5 was recognized as the "Best Vape Mod" in 2024 and continues to lead the market two years later [1] - The DRAG series has a history of technological advancements, including instant-inhaling capabilities and rapid igniting speeds, with the DRAG 6 expected to continue this legacy [2] Group 2: Marketing and Promotions - VOOPOO has initiated an Early Bird event offering 50% OFF vouchers and a chance to win 166 free DRAG 6 coupons, encouraging community engagement [3] - The company will showcase the DRAG 6 at Vapexpo Paris 2026 and TPE26 in March, allowing users to experience the product firsthand [3]